The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020crobial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Business Vision And Model

 

Mission To develop BSG005, including any derivatives and novel formulations of this compound, into the new first line treatment choice for invasive fungal disease, to save thousands of lives every year while generating significant returns to the company’s shareholders. The company intends to achieve its mission through a combination of academic and commercial excellence, strategic partnerships and highly experienced leadership

 

 Vision To emerge over the next five years as a leading international biotechnology company in the global fight against fungal infections, building its own commercial infrastructure and strong partnerships with pharmaceutical companies, key opinion leaders, NGOs and government agencies all over the world

 

 


Business model

 

Biosergen intends to employ the vast majority of its financial and organisational resources on clinical development  

 

The Company’s continuing research activities will be conducted in collaboration with its academic partners  

 

In time, the Company will establish the limited sales
and marketing infrastructure necessary to cover specific regions, first and foremost the United States and Europe